Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kinross Gold Corporation (KGC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Kinross Gold CorporationTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Kinross Gold Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Kinross Gold Corporation trades at $27.57 (market cap $32.29B), while Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B). The key difference: Kinross Gold Corporation is far larger — about 17.8× Recursion Pharmaceuticals Inc's market cap, and Kinross Gold Corporation pays a 0.59% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

KGCRXRX
Market Cap
$32.29B$1.81B
Sector
Basic MaterialsHealth
52-Week High
$38.06$6.79
52-Week Low
$18.70$2.84
Enterprise Value
$30.37B$1.33B
Dividend Yield
0.59%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kinross Gold Corporation

Kinross Gold (KGC) trades at $27.70, up 1.09% today, with a bullish technical signal from moving averages but overbought RSI levels. The company demonstrates robust fundamentals, with Q2 2026 EPS beating estimates at $0.71 versus $0.66 expected, and strong cash flow growth, with 2025 operating cash flow at $3.76 billion. Recent news includes a credit rating upgrade to 'BBB' by S&P Global Ratings on August 6, 2026, and ongoing project developments like Lobo-Marte.

The outlook is positive, supported by earnings beats, rising gold prices, and a consensus price target of $37.20, implying 34% upside. Risks include cost pressures and gold price volatility, but institutional buying and a 58.6% analyst buy rating suggest confidence in continued growth.

Recursion Pharmaceuticals Inc

RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.

Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Kinross Gold Corporation

Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.

Read more on KGC

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX